Highlights of the Merger:
- Adds complementary products for NGS library preparation and genetic analysis to Takara Bio Group's global reagent product mix
- Expands Takara Bio Group's product portfolio into IVF and other clinical markets
- Strengthens Takara Bio Group's leadership in low-input and single-cell pre-analytical sample preparation
- Increases access of Rubicon's technologies and products by leveraging Takara Bio Group's research market expertise and global commercial reach
"This acquisition builds on Takara Bio Group's commitment to develop a differentiated NGS portfolio and provide our customers with a broader offering of genetic analysis solutions, particularly in the area of library preparation," said Carol Lou, President, TBUSA. "Rubicon's technologies and products complement our current expertise and offerings such as our portfolio of cDNA synthesis, low-input and single cell RNA-seq products based on our proprietary SMART® technology. We welcome Rubicon into the Takara Bio Group and are looking forward to strengthening and expanding our product offerings in the fields of genomics, sequencing, single-cell and clinical applications with their unique technologies."
"Joining Takara Bio Group provides access to their global reach and research market expertise that will accelerate the adoption of our highly sensitive NGS library preparation and genetic analysis workflow solutions by more laboratories around the world," said Rubicon CEO James Koziarz, Ph.D., "We are excited to have the opportunity to combine our proprietary suite of products with those of Takara Bio Group to provide more comprehensive solutions to researchers and clinical labs."
Rubicon's technology is also complementary with the WaferGen Bio-systems, Inc. instrument platforms and technologies which TBUSH announced earlier this year it is acquiring, and anticipates will close in March 2017. The combined acquisitions are synergistic and will allow Takara Bio Group to provide the exciting benefits of the combined portfolios to the life science community.
The transaction is subject to customary closing conditions. Upon the effectiveness of the merger, TBUSH will own all outstanding capital stock of Rubicon for a purchase price of approximately 75 million dollars.
GCA Advisors, LLC was exclusive financial advisor to TBUSH and BroadOak Partners, LLC was exclusive financial advisor to Rubicon. Morrison & Foerster LLP acted as legal counsel to TBUSH while Honigman Miller Schwartz and Cohn LLP acted as legal counsel for Rubicon.
About Takara Bio Inc.
Takara Bio Inc. is an innovative biotechnology company based in Shiga, Japan. As a world leader in biotechnology research and development, Takara Bio was the first company to market PCR technology in Japan and is also the developer of the RetroNectin® reagent, which is used as a world standard in gene therapy protocols. In addition to providing research reagents and equipment to the life science research market, Takara Bio has active research and product development activities in the fields of gene and cell-based therapy and agricultural biotechnology; and is committed to preventing disease and improving the quality of life for all people through the use of biotechnology. Through strategic alliances with other industry leaders, Takara Bio aims to extend its reach around the world. More information is available at takara-bio.com.
About Takara Bio USA, Inc.
Takara Bio USA, Inc. (formerly Clontech Laboratories, Inc.), a wholly owned subsidiary of Takara Bio Inc., develops, manufactures, and distributes a wide range of life science research reagents under the Takara®, Clontech® and Cellartis® brands. Key products include SMARTer® cDNA synthesis kits for a variety of samples and applications, including NGS; high-performance qPCR and PCR reagents (including the Takara Ex Taq®, Takara LA Taq®, Titanium®, and Advantage® enzymes); Cellartis stem cells and stem cell reagents; RT enzymes and SMART® library construction kits; the innovative In-Fusion® cloning system; Guide-it™ gene editing tools; Tet-based inducible gene expression systems; and Living Colors® fluorescent proteins. These and other products support applications including NGS; gene discovery, regulation, and function studies; protein expression and purification; gene editing and stem cell studies; and plant and food research. For more information, visit takarabio.com.
About Rubicon Genomics
Rubicon Genomics develops innovative, high quality, nucleic acid library preparation and companion products for research applications that enable easy, reliable, and highly sensitive analysis of samples. Rubicon is committed to teamwork and continuous improvement to provide excellence to our customers, shareholders, and employees. Privately-held Rubicon is located in Ann Arbor, Michigan. For more information, visit rubicongenomics.com.
To view the original version on PR Newswire, visit:http://www.prnewswire.com/news-releases/takara-bio-usa-holdings-and-rubicon-genomics-announce-merger-agreement-300379230.html
SOURCE Takara Bio USA, Inc.